Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.21 CAD | +1.90% | +5.94% | +191.82% |
05-14 | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
04-22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+191.82% | 158M | |
+33.34% | 49.46B | |
+1.79% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.76% | 26.61B | |
-21.85% | 18.64B | |
+7.87% | 13.16B | |
+29.51% | 12.55B | |
+23.72% | 12.1B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Cardiol Therapeutics : Upgraded to Outperform at Raymond James as First Patient Enrolled in Clinical Trial